ARTBIO Strengthens Leadership with Strategic Board Appointments to Advance Cancer Therapies
ARTBIO enhances its board with four industry veterans to propel its innovative alpha radioligand therapies, marking a pivotal step in its mission to revolutionize cancer treatment.
ARTBIO, Inc., a clinical-stage radiopharmaceutical company at the forefront of developing alpha radioligand therapies (ARTs), has announced the addition of four distinguished professionals to its Board of Directors. This strategic move underscores the company's dedication to leveraging unparalleled expertise to accelerate the development of its groundbreaking cancer treatments. The new board members bring a wealth of experience in biotech investments, healthcare strategy, pharmaceutical operations, and capital markets, positioning ARTBIO for its next phase of growth.
The appointments include Maha Katabi, Ph.D., CFA, a General Partner at Sofinnova Investments; Robert Mittendorff, M.D., MBA, Head of Healthcare at B Capital Group; Julie O’Neill, MBA, an independent director with extensive experience in pharmaceutical manufacturing; and Gabe Gelman, Head of Capital Solutions at Baker Bros. Advisors LP. Their collective expertise is expected to guide ARTBIO through its strategic expansion and program development efforts.
In a related development, ARTBIO co-founder Roy Larsen, Ph.D., will transition from the Board of Directors to a newly established Technical Advisory Board. Dr. Larsen's pioneering work in radiopharmaceuticals has been instrumental in ARTBIO's journey, and his continued involvement ensures the company remains at the cutting edge of cancer therapy innovation.
ARTBIO's lead program, AB001, targeting metastatic castration-resistant prostate cancer, is currently in first-in-human trials. The company's unique approach, utilizing the alpha-precursor isotope Pb212 and its AlphaDirect technology, aims to set new standards in the efficacy and safety of cancer treatments. For more information on ARTBIO's innovative work, visit https://www.artbio.com.
The expansion of ARTBIO's board and the strategic shift of its co-founder to a technical advisory role highlight the company's commitment to advancing cancer care through innovative science and leadership. With these changes, ARTBIO is poised to make significant strides in the development of alpha radioligand therapies, offering hope to patients worldwide.